Klaas Schildknegt Selected Research

Type 2 Diabetes Mellitus (MODY)

1/2018

Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Klaas Schildknegt Research Topics

Disease

2	Alzheimer Disease (Alzheimer's Disease) 07/2018 - 01/2018
1	COVID-19 10/2023
1	Type 2 Diabetes Mellitus (MODY) 01/2018
1	Communicable Diseases (Infectious Diseases) 07/2016
1	Obesity 06/2007
1	Body Weight (Weight, Body) 06/2007

Drug/Important Bio-Agent (IBA)

1	lufotrelvirIBA 10/2023
1	Phosphates (Orthophosphate)IBA 10/2023
1	ProdrugsIBA 10/2023
1	imidazoleIBA 07/2018
1	SAM-760IBA 07/2018
1	SodiumIBA 01/2018
1	ertugliflozinIBA 01/2018
1	Amyloid (Amyloid Fibrils)IBA 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	Immunoconjugates (Immunoconjugate)IBA 07/2016
1	CP-809,101IBA 06/2007

Therapy/Procedure

2	Therapeutics 10/2023 - 07/2016
1	Intravenous Infusions 10/2023